Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pelthos Therapeutics Inc. (PTHS : AMEX)

• Company Description    Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $22.99 Daily Weekly Monthly 20 Day Moving Average: 27,325 shares Shares Outstanding: 3.09 (millions) Market Capitalization: $70.96 (millions) Beta: 4.04 52 Week High: $37.50 52 Week Low: $5.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.71% -34.58% 12 Week -30.98% -32.96% Year To Date 258.66% 218.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4020 STIRRUP CREEK DRIVE SUITE 110 - DURHAM,NC 27703 USA ph: 919-908-2400 fax: - mmoyer@lifesciadvisors.com http://www.pelthos.com

• General Corporate Information    Officers Francis Knuettel II - Chief Executive Officer and President; Chief Finan Ezra Friedberg - Director Todd Davis - Director Richard Malamut - Director Chia-Lin Simmons - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171126204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 3.09 Most Recent Split Date: 7.00 (0.10:1) Beta: 4.04 Market Capitalization: $70.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-16.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.21 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -82.76% vs. Previous Quarter: 1.49% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -210.32 06/30/25 - - 03/31/25 - - ROA 09/30/25 - -72.82 06/30/25 - -689.60 03/31/25 - -419.25 Current Ratio 09/30/25 - 2.01 06/30/25 - 0.11 03/31/25 - 0.18 Quick Ratio 09/30/25 - 1.04 06/30/25 - 0.11 03/31/25 - 0.18 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -324.68 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 18.99 06/30/25 - -9.64 03/31/25 - -6.83 Inventory Turnover 09/30/25 - 0.38 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - 0.00 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©